Immunic and the university medical center goettingen sign license agreement covering the combination of dhodh inhibitors and nucleoside analogues to treat viral infections, including covid-19

New york and goettingen, germany, sept. 22, 2021 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the execution of an in-license agreement with the university medical center goettingen, germany, covering the combination of dhodh inhibitors and nucleoside analogues to treat viral infections (covid-19 and influenza).
IMUX Ratings Summary
IMUX Quant Ranking